What BPC-157 is

BPC-157 is one of the most heavily-researched regenerative peptides in the research-chemical catalog. The compound has been studied in hundreds of preclinical models spanning tendon and ligament injury, muscle laceration, GI ulceration, bone healing, and CNS injury, and it remains an active target of published academic research.

Structurally, BPC-157 is a stable 15-amino-acid partial sequence derived from a larger human gastric protective protein (originally called "Body Protection Compound"). TB-500 is a synthetic fragment of the naturally-occurring Thymosin Beta-4 protein — the fragment that carries the actin-binding motif responsible for TB-4's tissue-repair activity. The "Wolverine" stack combines both.

Mechanism of action

The two peptides converge on regenerative biology through different upstream pathways:

• BPC-157 upregulates VEGF (angiogenesis), modulates the nitric-oxide (NO) synthase pathway, augments 5-HT and dopaminergic tone in specific CNS regions, and enhances fibroblast migration to the wound bed. In preclinical injury models, its most consistent effect is accelerated re-establishment of blood supply to damaged tissue.
• TB-500 binds monomeric G-actin, promoting cytoskeletal remodeling required for cell migration, endothelial-cell mobilization, and neovascularization. The active tetrapeptide sequence (Ac-SDKP) has independent anti-fibrotic activity in cardiac and dermal wound-healing literature.

The synergy that the "Wolverine stack" literature proposes: BPC-157 stimulates VEGF-driven angiogenesis while TB-500 supplies the actin-remodeling machinery for the cells migrating into the new vasculature.

Published research context

• BPC-157 has been studied in rodent Achilles tendon transection models (Chang et al., Krivic et al.) with published data showing accelerated recovery of tensile strength.
• Muscle-crush and laceration models report faster recovery of functional cross-sectional area with subcutaneous or intramuscular BPC-157 dosing.
• GI-ulceration models (indomethacin, ethanol, cysteamine) consistently show ulcer-area reduction — the original indication that drove the compound's development.
• TB-500 / Thymosin Beta-4 has published data in corneal wound healing, cardiac ischemia-reperfusion, and dermal wound closure.

Human clinical data for both compounds remain limited and largely non-randomized; most rigorous evidence is preclinical. Publications cited above are the standard references, not exhaustive.

Dosing ranges reported in the research literature

Published animal-model doses translate imperfectly to any research protocol and are reproduced here as reference only:

• BPC-157: preclinical doses typically 10 µg/kg to 500 µg/kg, subcutaneous or intraperitoneal. Research-scale protocols in the peptide literature typically discuss 200–500 µg once or twice daily.
• TB-500: preclinical doses 2–10 mg/kg in some models; research-scale protocols commonly discuss loading of 2–2.5 mg twice weekly for 4–6 weeks, followed by a maintenance phase.

Route in the peptide-research literature is overwhelmingly subcutaneous; some protocols use targeted intramuscular injection near the injury site.

Half-life and expected onset

BPC-157's plasma half-life is short (single-digit hours in rodent PK), but its downstream effects on VEGF expression persist beyond plasma clearance — which is why once-daily dosing is common in the literature despite the short PK. TB-500 has a longer functional duration due to its actin-binding activity in tissue. Onset of measurable functional improvement in published models is typically 2–4 weeks; complete tendon-strength recovery in rodent models runs 4–8 weeks.

Stacking considerations discussed in the literature

• BPC-157 + TB-500 ("Wolverine") — the canonical regenerative stack.
• BPC-157 + GHK-Cu — regenerative + skin/vascular remodeling.
• BPC-157 + Ipamorelin/CJC-1295 — regenerative + growth-hormone axis for models focused on connective-tissue anabolism.

Route, timing, and dose separation vary by protocol; researchers should design based on the specific injury model being studied.

Standard laboratory handling

Every research vial from PX1 is a lyophilized (freeze-dried) powder sealed under vacuum in a Type-I borosilicate vial with a butyl-rubber stopper and aluminum crimp seal. Correct handling preserves potency and prevents peptide-bond hydrolysis that degrades the active molecule.

• Storage before reconstitution: 2–8 °C refrigerator is ideal; freezer (−20 °C) for storage beyond six months. Short excursions to room temperature during shipping do not compromise integrity — the compound is stable in its solid state.
• Reconstitution solvent: bacteriostatic water for injection (0.9% benzyl alcohol) is standard for research protocols that require multiple sampling events from the same vial. Sterile water is acceptable for single-use protocols.
• Reconstitution technique: inject the diluent slowly against the vial wall — never directly onto the lyophilized cake. Swirl gently; do not shake. Shaking introduces air, denatures peptide secondary structure, and can create insoluble aggregates.
• Post-reconstitution storage: 2–8 °C refrigerated, typically stable 21–30 days depending on the peptide. Freezing a reconstituted solution repeatedly is not recommended — freeze/thaw cycles are the single biggest driver of loss-of-potency in the research literature.
• Concentration math: volume of diluent (mL) = peptide mass (mg) ÷ desired concentration (mg/mL). Example: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL.

Purity, identity and COA verification

The single most important due-diligence step when sourcing BPC-157 for research is reviewing the lot-specific Certificate of Analysis (COA). A credible COA contains:

1. HPLC purity value with chromatogram — target ≥ 98% for injectable-grade research peptides; ≥ 99% for the newest generation of GLP/incretin compounds. A single well-defined main peak with baseline separation from impurities is what you are looking for.
2. Identity confirmation by mass spectrometry — LC-MS or MALDI-TOF confirming the observed molecular weight matches the theoretical mass to within instrument tolerance.
3. Endotoxin (LAL / kinetic-chromogenic) result — expressed in EU/mg; USP guidance for parenteral products is well below 5 EU/kg body-weight equivalent, and reputable suppliers report < 10 EU/mg on the COA.
4. Sterility result — USP <71> membrane filtration or direct inoculation, both bacterial and fungal.
5. Karl Fischer moisture — target < 5% residual water for a properly lyophilized cake.
6. Residual-solvent screen — DMF, TFA, DCM, acetonitrile below ICH Q3C thresholds.

PX1 publishes lot-specific COAs at /purity-reports. If you have received a shipment and want to verify the exact lot documentation for BPC-157, cross-reference the lot number on the vial label to the COA PDF.

Why researchers choose PX1 for BPC-157

• 100% U.S. synthesis, lyophilization, and fill/finish. No repackaged imports. Every step from raw amino acid to sealed vial happens under one U.S. GMP-compliant roof.
• Third-party ISO-17025 testing on every lot. Purity, identity, endotoxin, sterility, moisture, and residual-solvent testing performed by an independent analytical laboratory whose data appears on the shipped COA.
• Chain-of-custody documentation from raw material through final QC — the same documentation package a clinical CDMO would provide.
• Same-day shipping on in-stock catalog items ordered before 3 p.m. ET, with insulated packaging and cold-pack where appropriate.

Common researcher questions

Q: How do I know the vial contents match the label? Compare the lot number on the vial to the lot number on the COA. The COA lists HPLC purity, identity by mass-spec, and endotoxin. If any of the three is missing or the lot doesn't match, don't proceed.

Q: Can I use bacteriostatic water past its printed expiration? Bacteriostatic water carries a manufacturer-assigned expiration for the sealed vial. Once punctured, USP guidance limits multi-dose vials to 28 days at 2–8 °C. Beyond 28 days, discard.

Q: Is refrigeration required during shipping? For most lyophilized peptides, no — the solid form is stable at ambient temperature for weeks. Some compounds (IGF-1 LR3, certain GH-releasing peptides) benefit from cold-chain shipping. PX1 uses insulated packaging for temperature-sensitive lines.

Q: What if the reconstituted solution is cloudy? Cloudiness indicates aggregation or precipitation and the solution should not be used. Common causes: over-vigorous shaking, incompatible diluent, or a vial that has passed its stability window.

Research use disclaimer

BPC-157 is supplied to licensed research professionals for in vitro and in vivo laboratory research only. Products are not intended for human consumption, veterinary use, diagnostic use, therapeutic use, or as a food additive or cosmetic. Nothing on this page constitutes medical advice. Consult the primary literature — clinical-trial registrations, peer-reviewed publications — before designing any protocol. Compounds discussed here are investigational; several have not received FDA approval for any indication.

Additional PX1 references

• Complete research library
• Lot-specific purity reports
• Product catalog
• Manufacturing & QC standards